Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
Want to see TSE:LEXT full AI Analyst Report?
Top Page
Lexston Life Sciences Corp.
(LEXT)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.05
▼(-48.00% Downside)
Action:Downgraded
Date:05/21/26
The score is driven primarily by weak financial performance (zero recent revenue, persistent losses, and ongoing cash burn), partially offset by the lack of balance-sheet debt. Technicals add pressure as the stock trades below key moving averages with negative MACD, while valuation is constrained by negative earnings and no indicated dividend support.
Positive Factors
Low Leverage
Having no reported debt materially reduces refinancing and interest burden risk over the next several months. This preserves financial flexibility to fund exploration, restructure operations or wait for commodity tailwinds without imminent default or forced asset sales, supporting runway.
Negative Factors
No Recent Revenue
Sustained zero revenue across multiple recent periods is a core structural weakness: it shows the company lacks ongoing commercial sales or production. Without recurring revenue the firm remains dependent on financing or asset sales, undermining durable viability and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Having no reported debt materially reduces refinancing and interest burden risk over the next several months. This preserves financial flexibility to fund exploration, restructure operations or wait for commodity tailwinds without imminent default or forced asset sales, supporting runway.
Read all positive factors
Lexston Life Sciences Corp. (LEXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.38M
Dividend YieldN/A
Average Volume (3M)40.70K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS Growth55.26%
CountryCA
EmployeesN/A
SectorBasic Materials
Sector Strength58
IndustryGold
Share Statistics
EPS (TTM)-0.14
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lexston Life Sciences Corp. Business Overview & Revenue Model
Company Description
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing a...
Lexston Life Sciences Corp. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Aug 2025 | Aug 2024 | May 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 361.01K | 149.11K |
| Gross Profit | 0.00 | 0.00 | -26.39K | -29.80K | 241.49K | 60.10K |
| EBITDA | -1.45M | -1.54M | -648.32K | -841.73K | -2.29M | -479.82K |
| Net Income | -1.53M | -1.62M | -867.71K | -1.11M | -2.32M | -876.13K |
Balance Sheet | ||||||
| Total Assets | 1.16M | 279.49K | 750.95K | 814.30K | 952.80K | 1.10M |
| Cash, Cash Equivalents and Short-Term Investments | 278.52K | 2.32K | 390.40K | 511.00K | 590.49K | 949.17K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 130.55K | 208.82K | 39.87K | 11.21K | 79.09K | 38.81K |
| Stockholders Equity | 1.02M | 70.67K | 711.08K | 803.10K | 873.71K | 1.06M |
Cash Flow | ||||||
| Free Cash Flow | -1.02M | -1.19M | -723.16K | -987.74K | -1.40M | -608.63K |
| Operating Cash Flow | -1.02M | -1.19M | -523.18K | -987.74K | -1.40M | -483.16K |
| Investing Cash Flow | -58.63K | -10.00K | -199.99K | 0.00 | -109.97K | 812.32K |
| Financing Cash Flow | 1.30M | 814.66K | 602.57K | 908.24K | 1.15M | 620.01K |
Lexston Life Sciences Corp. Technical Analysis
Negative
0.10
Price Trends
0.07
Negative
0.08
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
44.18
Neutral
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LEXT, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.18 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LEXT.
Lexston Life Sciences Corp. Peers Comparison
UnderperformOutperform
Sector (61)
TSE:LEXT
Lexston Life Sciences Corp.
0.06
-0.09
-60.71%
TSE:LSD.H
Lightspeed Discoveries
0.07
0.04
133.33%
TSE:LCR
NeonMind Biosciences Inc
0.04
0.02
100.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.